Research
Molecular
Recent innovations in bariatric research include pharmacological therapies targeting GLP-1 receptors, minimally invasive procedures, and genetic and microbiome-based strategies.
These innovations may provide new options for obesity treatment.
StrongSupportsmedium confidence
Innovations in bariatric research were categorized into three main domains: (1) pharmacological therapies targeting glucagon-like peptide-1 (GLP-1) receptors, lipolysis, and metabolic pathways; (2) minimally invasive endoscopic and device-assisted interventions; and (3) novel genetic and microbiome-based strategies.
Why this rating
Based on systematic review methodology.
Source
Chemobiology of Obesity and Advances in Bariatrics: A Systematic Review
Chinua Onyebuchi et al. · medtigo Journal of Medicine · 2025
DOI 10.63096/medtigo30623130
Meta-analysisCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Key chemobiological mechanisms implicated in obesity include dysregulated leptin-ghrelin signaling, chronic low-grade inflammation, and altered adipokine profiles.Strong
- Integrating pharmacological, minimally invasive, and genetic strategies may enhance long-term weight management and metabolic outcomes.Strong
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →